(Bloomberg) — An overlooked drug bought by a biotech company for a mere $6.6 million a decade ago could become one of the biggest selling cancer treatments ever. Those high expectations have its maker, Pharmacyclics Inc., considering selling itself in a deal that could be worth as much as $18 billion. The Sunnyvale, California-based company […]
Join the fight for freedom
Be the first to know: Stories from The Washington Informer in your inbox each weekday.